Home/CheMedImmune/Priscilla S. Redd, PhD
PS

Priscilla S. Redd, PhD

Chief Executive Officer and Chief Scientific Officer

CheMedImmune

CheMedImmune Pipeline

DrugIndicationPhase
OPN Blockade mAbs (100D3/103D6)Colorectal Cancer, Pancreatic CancerPre-clinical
IFNA2-LNP01Lung MetastasesPre-clinical
Epigenetic Dual TargetingColorectal Cancer (ICI-resistant)Pre-clinical